• Dogwood Therapeutics investor presentation outlined a non-opioid pain pipeline led by Halneuron injection for chemotherapy-induced neuropathic pain.
• Halneuron Phase 2b data readout targeted for fall; FDA end-of-Phase 2 submission planned for Q4.
• Program positioned around Nav1.7 sodium-channel blockade using tetrodotoxin, designed for peripheral pain modulation without central nervous system effects.
• Cash totaled USD 13.2 million on a March 31 pro forma basis; shares outstanding listed as 33,553.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.